Table of Contents

Research Articles

• Research Articles

  Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach

  Tanner M. Johanns, Jeffrey P. Ward, Christopher A. Miller, Courtney Wilson, Dale K. Kobayashi, Diane Bender, Yujie Fu, Anton Alexandrov, Elaine R. Mardis, Maxim N. Artyomov, Robert D. Schreiber and Gavin P. Dunn

  Cancer Immunol Res December 1 2016 4 (12) 1007-1015; DOI:10.1158/2326-6066.CIR-16-0156

  
  

  Immunogenomics were used to identify tumor-specific neoantigens in two well characterized models of glioblastoma. Endogenous immune responses harbored neoantigen-specific T cells within the brain and lymph nodes, providing a tractable system for additional preclinical immunotherapeutic studies in these systems.
• Research Articles

  Rescue of Tolerant CD8⁺ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes

  Lauryn E. Klevorn, Melissa M. Berrien-Elliott, Jinyun Yuan, Lindsey M. Kuehm, Gregory D. Felock, Sean A. Crowe and Ryan M. Teague

  Cancer Immunol Res December 1 2016 4 (12) 1016-1026; DOI:10.1158/2326-6066.CIR-16-0159

  
  

  Immunotherapy for cancer can be obstructed by immune tolerance, in which antitumor T cells are rendered dysfunctional in the tumor microenvironment. It is shown here that IL2:antibody complexes can reverse established T cell tolerance and restore antitumor immunity.
• Research Articles

  PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors

  Marcela A. Haro, Chad A. Littrell, Zhaojun Yin, Xuefei Huang and Karen M. Haas

  Cancer Immunol Res December 1 2016 4 (12) 1027-1037; DOI:10.1158/2326-6066.CIR-16-0184

  
  

  PD-1 regulates T-cell antitumor responses. PD-1 has now also been found to inhibit B-cell antitumor immunity that is based upon the recognition of tumor-specific glycans, revealing an alternative mechanism by which PD-1 blockade may elicit antitumor responses.
• Research Articles

  Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

  Mark M. Awad, Robert E. Jones, Hongye Liu, Patrick H. Lizotte, Elena V. Ivanova, Meghana Kulkarni, Grit S. Herter-Sprie, Xiaoyun Liao, Abigail A. Santos, Mark A. Bittinger, Lauren Keogh, Shohei Koyama, Christina Almonte, Jessie M. English, Julianne Barlow, William G. Richards, David A. Barbie, Adam J. Bass, Scott J. Rodig, F. Stephen Hodi, Kai W. Wucherpfennig, Pasi A. Jänne, Lynette M. Sholl, Peter S. Hammerman, Kwok-Kin Wong and Raphael Bueno

  Cancer Immunol Res December 1 2016 4 (12) 1038-1048; DOI:10.1158/2326-6066.CIR-16-0171

  
  

  In malignant pleural mesothelioma, immunohistochemical expression of PD-L1 does not accurately predict whether patients respond to treatment with PD-1 pathway inhibitors. Comprehensive immunoprofiling by flow cytometry uncovered immunophenotypes that improve our understanding of response and resistance to checkpoint blockade.
• Research Articles

  Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells

  Yoshihiro Ohue, Koji Kurose, Ryohei Nozawa, Midori Isobe, Yumi Nishio, Tomonori Tanaka, Yoshinori Doki, Takashi Hori, Junya Fukuoka, Mikio Oka and Eiichi Nakayama

  Cancer Immunol Res December 1 2016 4 (12) 1049-1060; DOI:10.1158/2326-6066.CIR-15-0266

  
  

  The survival of lung adenocarcinoma patients could be predicted with the use of a discriminant function using as parameters tumor cell expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a), and CD4 and CD8 T-cell infiltration.
• Research Articles

  Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

  Ellen Moore, Paul E. Clavijo, Ruth Davis, Harrison Cash, Carter Van Waes, Young Kim and Clint Allen

  Cancer Immunol Res December 1 2016 4 (12) 1061-1071; DOI:10.1158/2326-6066.CIR-16-0104

  
  

  Many patients with head and neck squamous cell carcinomas do not respond to current immunotherapies. Antitumor responses, with protective memory and control of distant tumors, developed in mouse models after treatment with PD-L1 mAb and synthetic cyclic dinucleotides.
• Research Articles | AuthorChoice

  Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

  Kipp Weiskopf, Katie L. Anderson, Daisuke Ito, Peter J. Schnorr, Hirotaka Tomiyasu, Aaron M. Ring, Kristin Bloink, Jem Efe, Sarah Rue, David Lowery, Amira Barkal, Susan Prohaska, Kelly M. McKenna, Ingrid Cornax, Timothy D. O'Brien, M. Gerard O'Sullivan, Irving L. Weissman and Jaime F. Modiano

  Cancer Immunol Res December 1 2016 4 (12) 1072-1087; DOI:10.1158/2326-6066.CIR-16-0105

  
  

  Targeting CD47 and CD20 to stimulate macrophage phagocytosis was effective in preclinical xenograft models of canine lymphoma in mice. This immunotherapeutic strategy has the potential to benefit companion animals and to inform future targeting studies in humans.